These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 25632203)

  • 1. Vitamin D status and viral response to therapy in hepatitis C infected children.
    Eltayeb AA; Abdou MA; Abdel-aal AM; Othman MH
    World J Gastroenterol; 2015 Jan; 21(4):1284-91. PubMed ID: 25632203
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study.
    Terrier B; Lapidus N; Pol S; Serfaty L; Ratziu V; Asselah T; Thibault V; Souberbielle JC; Carrat F; Cacoub P
    World J Gastroenterol; 2015 May; 21(18):5647-53. PubMed ID: 25987791
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vitamin D improves viral response in hepatitis C genotype 2-3 naïve patients.
    Nimer A; Mouch A
    World J Gastroenterol; 2012 Feb; 18(8):800-5. PubMed ID: 22371640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients.
    Abu-Mouch S; Fireman Z; Jarchovsky J; Zeina AR; Assy N
    World J Gastroenterol; 2011 Dec; 17(47):5184-90. PubMed ID: 22215943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baseline anti-NS4a antibodies in combination with on-treatment quantitative HCV-RNA reliably identifies nonresponders to pegylated interferon-ribavirin combination therapy after 4 weeks of treatment.
    Orlent H; Desombere I; Hansen B; Van Vlierberghe H; Haagmans B; De Knegt RJ; Schalm SW; Leroux-Roels G; Janssen HL;
    Eur J Gastroenterol Hepatol; 2010 Dec; 22(12):1443-8. PubMed ID: 21389795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin.
    Esmat G; El Raziky M; Elsharkawy A; Sabry D; Hassany M; Ahmed A; Assem N; El Kassas M; Doss W
    J Interferon Cytokine Res; 2015 Jan; 35(1):49-54. PubMed ID: 25061714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized study comparing vitamin D3 and 1α-Hydroxyvitamin D3 in combination with pegylated interferon/ribavirin therapy for chronic hepatitis C.
    Omori-Mizuno Y; Nakayama N; Inao M; Funyu J; Asabe S; Tomita K; Nishikawa K; Hosoda Y; Tanaka M; Hashimoto Y; Yakabi K; Koshima Y; Mochida S
    J Gastroenterol Hepatol; 2015 Sep; 30(9):1384-90. PubMed ID: 25778685
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfected patients.
    Mandorfer M; Reiberger T; Payer BA; Ferlitsch A; Breitenecker F; Aichelburg MC; Obermayer-Pietsch B; Rieger A; Trauner M; Peck-Radosavljevic M;
    AIDS; 2013 Jan; 27(2):227-32. PubMed ID: 23238552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of hepatitis C virus (HCV) RNA load in platelets of HCV-monoinfected patients receiving antiviral therapy.
    Espírito-Santo MP; Brandão-Mello CE; Marques VA; Lampe E; Almeida AJ
    Ann Hepatol; 2013; 12(3):373-9. PubMed ID: 23619253
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect and safety of the treatment of recurrent hepatitis C infection after orthotopic liver transplantation with pegylated interferon α2b and ribavirin.
    Perrakis A; Yedibela S; Schuhmann S; Croner R; Schellerer V; Demir R; Hohenberger W; Müller V
    Transplant Proc; 2011 Dec; 43(10):3824-8. PubMed ID: 22172854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
    Mohamed AA; Sabry NA; Abbassi MM; Ibrahim WA; Ali-Eldin ZA
    Acta Gastroenterol Belg; 2013 Mar; 76(1):38-44. PubMed ID: 23650781
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between vitamin D and hepatitis C virus infection: a meta-analysis.
    Villar LM; Del Campo JA; Ranchal I; Lampe E; Romero-Gomez M
    World J Gastroenterol; 2013 Sep; 19(35):5917-24. PubMed ID: 24124339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.
    Niederau C; Mauss S; Böker K; Lutz T; Heyne R; Moog G; John C; Witthöft T; Alshuth U; Hüppe D
    Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):65-73. PubMed ID: 23751351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C.
    Zeuzem S; Buggisch P; Agarwal K; Marcellin P; Sereni D; Klinker H; Moreno C; Zarski JP; Horsmans Y; Mo H; Arterburn S; Knox S; Oldach D; McHutchison JG; Manns MP; Foster GR
    Hepatology; 2012 Mar; 55(3):749-58. PubMed ID: 22006408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Peginterferon alpha-2a and ribavirin in patients with hepatitis C virus genotype 1 infection with persistently normal alanine aminotransferase levels.
    Calleja JL; García-Samaniego J; Ruiz-Antorán B; Trapero M; Morillas R; de la Revilla J; Erdozaín JC; Espinosa MD; Suárez D; Solá R; Romero-Gómez M; Baños F; Alvarez MA;
    J Gastroenterol Hepatol; 2012 Nov; 27(11):1705-10. PubMed ID: 22742958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic effects of pegylated interferon plus ribavirin in chronic hepatitis C patients with occult hepatitis B virus dual infection.
    Chen LW; Chien RN; Yen CL; Chang JJ; Liu CJ; Lin CL
    J Gastroenterol Hepatol; 2010 Feb; 25(2):259-63. PubMed ID: 19817959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal follow-up time to determine the sustained virological response in patients with chronic hepatitis C receiving pegylated-interferon and ribavirin.
    Namikawa M; Kakizaki S; Yata Y; Yamazaki Y; Horiguchi N; Sato K; Takagi H; Mori M
    J Gastroenterol Hepatol; 2012 Jan; 27(1):69-75. PubMed ID: 21649727
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy.
    Chen TM; Huang PT; Tsai MH; Lin LF; Liu CC; Ho KS; Siauw CP; Chao PL; Tung JN
    J Gastroenterol Hepatol; 2007 May; 22(5):669-75. PubMed ID: 17444854
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial.
    Yokoyama S; Takahashi S; Kawakami Y; Hayes CN; Kohno H; Kohno H; Tsuji K; Aisaka Y; Kira S; Yamashina K; Nonaka M; Moriya T; Kitamoto M; Aimitsu S; Nakanishi T; Kawakami H; Chayama K
    J Viral Hepat; 2014 May; 21(5):348-56. PubMed ID: 24716637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-density lipoprotein receptor genetic polymorphism in chronic hepatitis C virus Egyptian patients affects treatment response.
    Naga M; Amin M; Algendy D; Elbadry A; Fawzi M; Foda A; Esmat S; Sabry D; Rashed L; Gabal S; Kamal M
    World J Gastroenterol; 2015 Oct; 21(39):11141-51. PubMed ID: 26494968
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.